Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUP6M5)

Drug Name

BGB-15025 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting MEK kinase kinase 1 (MAP4K1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CFI-402411	DMB5KRA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
PF-07265028	DMJIXMO	Aggressive cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04649385) BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Treadwell Therapeutics.
3	Clinical pipeline report, company report or official report of Pfizer